Turnabout is fair playfor bone densitometry firm Hologic. The Waltham, MA, company raisedthe stakes this month in its legal battle with Lunar, filing acountersuit that accuses its competitor of infringing on its patents.The suit seeks to have three Lunar
Turnabout is fair playfor bone densitometry firm Hologic. The Waltham, MA, company raisedthe stakes this month in its legal battle with Lunar, filing acountersuit that accuses its competitor of infringing on its patents.The suit seeks to have three Lunar patents invalidated.
Lunar, of Madison, WI, fired the opening salvo last month whenit filed a federal lawsuit in U.S. District Court for the EasternDistrict of Wisconsin (SCAN 9/14/94). Lunar said that Hologic'smorphometry process is covered by three Lunar patents and askedthe court to overturn several Hologic patents.
Hologic's countersuit, filed in U.S. District Court for theDistrict of Massachusetts, charges that Lunar is infringing ontwo of Hologic's patents and asks for injunctive relief and damages.The complaint also seeks a declaration that Hologic does not infringeon three Lunar patents, which should be invalidated, accordingto the company. Finally, Hologic is asking for injunctive reliefand damages in connection with what the company said was "Lunar'sdissemination of false and misleading information which misrepresentsand disparages the quality of Hologic's bone densitometry products."
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.